CFS Investment Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

CFS Investment Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.6K	Hold	24,551	–	–	0.01%	355
2026 Q1	$50.1K	Hold	24,551	–	–	﹤0.01%	351
2025 Q4	$90.8K	Hold	24,551	–	–	0.01%	328
2025 Q3	$66.5K	Hold	24,551	–	–	﹤0.01%	340
2025 Q2	$24K	Hold	24,551	–	–	﹤0.01%	323
2025 Q1	$35K	Hold	24,551	–	–	﹤0.01%	307
2024 Q4	$54K	Hold	24,551	–	–	﹤0.01%	294
2024 Q3	$41K	Hold	24,551	–	–	﹤0.01%	290
2024 Q2	$55K	Hold	24,551	–	–	﹤0.01%	257
2024 Q1	$66K	Hold	24,551	–	–	0.01%	157
2023 Q4	$73K	Hold	24,551	–	–	0.01%	150
2023 Q3	$24K	Hold	24,551	–	–	﹤0.01%	160
2023 Q2	$34K	Hold	24,551	–	–	﹤0.01%	235
2023 Q1	$39K	Hold	24,551	–	–	0.01%	136
2022 Q4	$153K	Buy	+24,551	New	+$176K	0.03%	124

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

CFS Investment Advisory Services's ESPR Position: Q2 2026 in Review

CFS Investment Advisory Services held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 24,551 shares worth $77.6K. The position accounts for 0.01% of the portfolio, ranked #355.

CFS Investment Advisory Services first reported a position in ESPR in Q4 2022 and has held it in 15 quarters since. The position peaked at $153K in Q4 2022. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

CFS Investment Advisory Services held 24,551 shares of Esperion Therapeutics worth $77.6K as of Q2 2026.
CFS Investment Advisory Services left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up 0.01% of CFS Investment Advisory Services's portfolio in Q2 2026, its #355 holding.
CFS Investment Advisory Services first reported a position in Esperion Therapeutics in Q4 2022 and has held it in 15 quarters since.
CFS Investment Advisory Services's Esperion Therapeutics position peaked at $153K in Q4 2022.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on CFS Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.